Free Trial

Verve Therapeutics (VERV) Competitors

Verve Therapeutics logo
$11.13 0.00 (0.00%)
As of 07/25/2025

VERV vs. BEAM, PTCT, ACLX, MRUS, ZLAB, SRRK, ACAD, VKTX, SWTX, and PTGX

Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Beam Therapeutics (BEAM), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

Verve Therapeutics vs. Its Competitors

Beam Therapeutics (NASDAQ:BEAM) and Verve Therapeutics (NASDAQ:VERV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Verve Therapeutics has a net margin of -303.64% compared to Beam Therapeutics' net margin of -609.24%. Verve Therapeutics' return on equity of -35.81% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-609.24% -44.24% -30.97%
Verve Therapeutics -303.64%-35.81%-27.57%

In the previous week, Beam Therapeutics had 4 more articles in the media than Verve Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 10 mentions for Verve Therapeutics. Beam Therapeutics' average media sentiment score of 0.66 beat Verve Therapeutics' score of 0.29 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verve Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Beam Therapeutics presently has a consensus target price of $48.75, indicating a potential upside of 124.45%. Verve Therapeutics has a consensus target price of $14.57, indicating a potential upside of 30.92%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Verve Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07
Verve Therapeutics
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 19.9% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Verve Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$63.52M34.39-$376.74M-$4.61-4.71
Verve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27

Beam Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Summary

Beam Therapeutics beats Verve Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Verve Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERV vs. The Competition

MetricVerve TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$992.13M$2.49B$5.70B$9.50B
Dividend YieldN/A1.65%4.58%4.00%
P/E Ratio-5.279.1828.3920.08
Price / Sales30.69609.56430.0899.95
Price / CashN/A165.2136.2258.56
Price / Book1.915.168.675.88
Net Income-$198.71M$30.99M$3.25B$258.89M
7 Day Performance2.02%7.73%4.30%3.70%
1 Month Performance-1.15%16.27%10.57%11.71%
1 Year Performance50.41%-1.88%35.68%17.98%

Verve Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERV
Verve Therapeutics
2.9798 of 5 stars
$11.13
flat
$14.57
+30.9%
+49.8%$992.13M$32.33M-5.27110News Coverage
Analyst Upgrade
BEAM
Beam Therapeutics
2.259 of 5 stars
$21.17
+0.0%
$48.75
+130.3%
-32.5%$2.13B$63.52M-4.59510Analyst Revision
PTCT
PTC Therapeutics
4.4387 of 5 stars
$49.46
+1.9%
$65.00
+31.4%
+33.3%$3.92B$806.78M7.601,410News Coverage
Positive News
Analyst Revision
ACLX
Arcellx
2.286 of 5 stars
$69.92
+1.4%
$111.23
+59.1%
+13.8%$3.85B$76.81M-23.3880News Coverage
Positive News
MRUS
Merus
1.8941 of 5 stars
$55.62
+2.1%
$84.64
+52.2%
+23.0%$3.85B$36.13M-13.6337Upcoming Earnings
ZLAB
Zai Lab
3.1271 of 5 stars
$34.28
+4.7%
$54.28
+58.3%
+97.0%$3.81B$398.99M-13.771,869Positive News
Gap Up
SRRK
Scholar Rock
3.43 of 5 stars
$38.59
+3.1%
$42.67
+10.6%
+312.2%$3.66B$33.19M-15.25140Positive News
ACAD
ACADIA Pharmaceuticals
4.1503 of 5 stars
$21.89
+4.3%
$27.88
+27.3%
+25.3%$3.66B$957.80M15.98510Positive News
Analyst Forecast
VKTX
Viking Therapeutics
4.8451 of 5 stars
$31.63
+1.7%
$87.15
+175.5%
-46.8%$3.55BN/A-27.5020Trending News
Earnings Report
Analyst Forecast
Analyst Revision
SWTX
SpringWorks Therapeutics
1.2655 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
PTGX
Protagonist Therapeutics
1.3746 of 5 stars
$55.23
+4.2%
$66.10
+19.7%
+32.7%$3.42B$434.43M73.64120News Coverage
Insider Trade

Related Companies and Tools


This page (NASDAQ:VERV) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners